本網站中所有資料(包括圖檔及文字檔),著作權皆屬本會所有(除另有註明者,或本會網站連結至外部之網站除外),如有引用,請確實註明出處來源。<完整資訊>
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
地址:115 台北市南港區忠孝東路七段508號9樓
電話:(02)2655-8168
傳真:(02)2655-7978
資料來源:https://www.reuters.com/article/us-abbvie-trials-idUSKBN17L2X7
AbbVie Inc said on Wednesday that its cancer drug, veliparib, failed to meet the main goals of two late-stage studies.
The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer and triple negative breast cancer.
Veliparib belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.
(Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza)